GB201122047D0 - Transgenic animals - Google Patents

Transgenic animals

Info

Publication number
GB201122047D0
GB201122047D0 GBGB1122047.2A GB201122047A GB201122047D0 GB 201122047 D0 GB201122047 D0 GB 201122047D0 GB 201122047 A GB201122047 A GB 201122047A GB 201122047 D0 GB201122047 D0 GB 201122047D0
Authority
GB
United Kingdom
Prior art keywords
transgenic animals
inactivated
mice
inter alia
variable regions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1122047.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45572821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201122047(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to GBGB1122047.2A priority Critical patent/GB201122047D0/en
Publication of GB201122047D0 publication Critical patent/GB201122047D0/en
Priority to AU2012343587A priority patent/AU2012343587B2/en
Priority to EP23201805.1A priority patent/EP4282879A3/en
Priority to EP15188522.5A priority patent/EP2989894B9/en
Priority to EP12795606.8A priority patent/EP2649184B1/en
Priority to BR112014013121A priority patent/BR112014013121A2/pt
Priority to DE202012013369.1U priority patent/DE202012013369U1/de
Priority to CA2857569A priority patent/CA2857569A1/en
Priority to EP17196214.5A priority patent/EP3298889A1/en
Priority to CN201280059193.7A priority patent/CN104160031B/zh
Priority to ES15188522T priority patent/ES2816899T3/es
Priority to DK12795606.8T priority patent/DK2649184T3/en
Priority to PCT/GB2012/052956 priority patent/WO2013079953A1/en
Priority to JP2014543973A priority patent/JP2015502149A/ja
Priority to HK13112514.7A priority patent/HK1185100B/en
Priority to US13/843,528 priority patent/US20130243759A1/en
Priority to US15/199,575 priority patent/US20160353719A1/en
Priority to AU2016101604A priority patent/AU2016101604B4/en
Priority to AU2016244295A priority patent/AU2016244295A1/en
Priority to JP2017235119A priority patent/JP2018038428A/ja
Priority to US15/955,216 priority patent/US20180295821A1/en
Priority to AU2018217308A priority patent/AU2018217308A1/en
Priority to US16/725,707 priority patent/US20200205384A1/en
Priority to JP2020092295A priority patent/JP2020124228A/ja
Priority to AU2021203905A priority patent/AU2021203905A1/en
Priority to JP2022128160A priority patent/JP2022159413A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1122047.2A 2011-12-02 2011-12-21 Transgenic animals Ceased GB201122047D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB1122047.2A GB201122047D0 (en) 2011-12-21 2011-12-21 Transgenic animals
JP2014543973A JP2015502149A (ja) 2011-12-02 2012-11-30 ヒト可変領域を保有している抗体を産生するために有用な繁殖可能遺伝子導入動物
EP17196214.5A EP3298889A1 (en) 2011-12-02 2012-11-30 Use of fertile transgenic animals for producing antibodies bearing human variable regions
DK12795606.8T DK2649184T3 (en) 2011-12-02 2012-11-30 USE OF FERTILIZED TRANSGENE ANIMALS FOR THE MANUFACTURE OF ANTIBODIES CARRYING HUMAN VARIABLE REGIONS
HK13112514.7A HK1185100B (en) 2011-12-02 2012-11-30 Use of fertile transgenic animals for producing antibodies bearing human variable regions
EP15188522.5A EP2989894B9 (en) 2011-12-02 2012-11-30 Use of fertile transgenic mice or rats for producing antibodies bearing human variable regions
EP12795606.8A EP2649184B1 (en) 2011-12-02 2012-11-30 Use of fertile transgenic animals for producing antibodies bearing human variable regions
BR112014013121A BR112014013121A2 (pt) 2011-12-02 2012-11-30 animais transgênicos férteis úteis para produção de antibióticos portando regiões variáveis humanas
DE202012013369.1U DE202012013369U1 (de) 2011-12-02 2012-11-30 Fertile transgene Tiere, brauchbar zum Herstellen von Antikörpern, die humane variable Regionen tragen
CA2857569A CA2857569A1 (en) 2011-12-02 2012-11-30 Transgenic animals
EP23201805.1A EP4282879A3 (en) 2011-12-02 2012-11-30 Use of fertile transgenic animals for producing antibodies bearing human variable regions
CN201280059193.7A CN104160031B (zh) 2011-12-02 2012-11-30 用于生产具有人可变区的抗体的可育的转基因动物
ES15188522T ES2816899T3 (es) 2011-12-02 2012-11-30 Uso de ratones o ratas transgénicos fértiles para la producción de anticuerpos que llevan regiones variables humanas
AU2012343587A AU2012343587B2 (en) 2011-12-02 2012-11-30 Fertile transgenic animals useful for producing antibodies bearing human variable regions
PCT/GB2012/052956 WO2013079953A1 (en) 2011-12-02 2012-11-30 Fertile transgenic animals useful for producing antibodies bearing human variable regions
US13/843,528 US20130243759A1 (en) 2011-12-21 2013-03-15 Transgenic Animals
US15/199,575 US20160353719A1 (en) 2011-12-21 2016-06-30 Transgenic Animals
AU2016101604A AU2016101604B4 (en) 2011-12-02 2016-09-12 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2016244295A AU2016244295A1 (en) 2011-12-02 2016-10-13 Fertile transgenic animals useful for producing antibodies bearing human variable regions
JP2017235119A JP2018038428A (ja) 2011-12-02 2017-12-07 ヒト可変領域を保有している抗体を産生するために有用な繁殖可能遺伝子導入動物
US15/955,216 US20180295821A1 (en) 2011-12-02 2018-04-17 Transgenic Animals
AU2018217308A AU2018217308A1 (en) 2011-12-02 2018-08-17 Fertile transgenic animals useful for producing antibodies bearing human variable regions
US16/725,707 US20200205384A1 (en) 2011-12-02 2019-12-23 Transgenic Animals
JP2020092295A JP2020124228A (ja) 2011-12-02 2020-05-27 ヒト可変領域を保有している抗体を産生するために有用な繁殖可能遺伝子導入動物
AU2021203905A AU2021203905A1 (en) 2011-12-02 2021-06-11 Fertile transgenic animals useful for producing antibodies bearing human variable regions
JP2022128160A JP2022159413A (ja) 2011-12-02 2022-08-10 ヒト可変領域を保有している抗体を産生するために有用な繁殖可能遺伝子導入動物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1122047.2A GB201122047D0 (en) 2011-12-21 2011-12-21 Transgenic animals

Publications (1)

Publication Number Publication Date
GB201122047D0 true GB201122047D0 (en) 2012-02-01

Family

ID=45572821

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1122047.2A Ceased GB201122047D0 (en) 2011-12-02 2011-12-21 Transgenic animals

Country Status (11)

Country Link
US (2) US20130243759A1 (enExample)
EP (4) EP2649184B1 (enExample)
JP (4) JP2015502149A (enExample)
CN (1) CN104160031B (enExample)
AU (5) AU2012343587B2 (enExample)
BR (1) BR112014013121A2 (enExample)
CA (1) CA2857569A1 (enExample)
DE (1) DE202012013369U1 (enExample)
ES (1) ES2816899T3 (enExample)
GB (1) GB201122047D0 (enExample)
WO (1) WO2013079953A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009329365B2 (en) * 2008-12-18 2016-01-14 Roger Kingdon Craig Non-human transgenic animals expressing humanised antibodies and use thereof
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
CA2807282A1 (en) 2010-08-02 2012-02-09 Regeneron Pharamaceuticals, Inc. Mice that make binding proteins comprising vl domains
HUE047687T2 (hu) 2011-02-25 2020-05-28 Regeneron Pharma ADAM6 egér
FI3865581T3 (fi) 2011-08-05 2024-11-02 Regeneron Pharma Humanisoituja universaaleja kevytketjun hiiriä
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR102762747B1 (ko) 2011-10-17 2025-02-05 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9706759B2 (en) 2011-12-20 2017-07-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
RS57118B1 (sr) 2012-03-16 2018-06-29 Regeneron Pharma Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
NZ730271A (en) 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
CN104302170B (zh) 2012-03-16 2016-09-28 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
KR102266274B1 (ko) 2012-06-12 2021-06-17 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
TR201810255T4 (tr) 2013-02-20 2018-08-27 Regeneron Pharma Modifiye edilmiş immunoglobulin ağır zincir sekanslarına sahip olan insan olmayan hayvanlar.
LT3501272T (lt) * 2013-03-13 2023-03-27 Regeneron Pharmaceuticals, Inc. Pelės, vykdančios imunoglobulino lengvosios grandinės riboto rinkinio raišką
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
WO2015040402A1 (en) 2013-09-18 2015-03-26 Kymab Limited Methods. cells & organisms
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
AU2014330922A1 (en) * 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
WO2015108102A1 (ja) 2014-01-15 2015-07-23 国立大学法人 群馬大学 Ａｔｐ可視化動物およびその用途
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
HUE042829T2 (hu) 2014-04-03 2019-07-29 Igm Biosciences Inc Módosított J-lánc
WO2015200805A2 (en) * 2014-06-26 2015-12-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
PL3265575T3 (pl) 2015-03-04 2021-11-29 Igm Biosciences, Inc. Cząsteczki wiążące CD20 i ich zastosowania
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
CN108463472A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j-链的结合分子
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
CN118185874A (zh) 2016-04-04 2024-06-14 苏黎世联邦理工学院 一种重组哺乳动物b细胞
CN111479916B (zh) * 2017-10-20 2024-10-22 弗莱德哈钦森癌症中心 用以产生被遗传修饰来表达所选抗体的b细胞的系统和方法
SI3773713T1 (sl) 2018-04-06 2025-08-29 Regeneron Pharmaceuticals, Inc. Protitelo, agonist leptinskega receptorja, za uporabo pri povečanju kostne mase pri osebi, ki trpi zaradi presnovne disfunkcije ali hipoleptinemije
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
DK3785536T4 (da) * 2019-08-28 2025-10-27 Trianni Inc Adam6-knockin-mus
CA3182925A1 (en) 2020-06-02 2021-12-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
CA3199879A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN118325896A (zh) * 2023-01-09 2024-07-12 上海交通大学医学院 一种抗体无功能等位基因小鼠模型及其构建方法和应用
TWI897189B (zh) 2023-01-18 2025-09-11 美商基利科學股份有限公司 具有經改變重鏈基因座之嵌合基因轉殖免疫球蛋白小鼠及其製造及使用方法
WO2025055311A1 (zh) * 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3320448C2 (de) 1983-06-07 1986-09-04 Elasto-Press Schmitz GmbH, 3250 Hameln Mangelband für Wäschemangeln
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
BE1007904A3 (nl) 1993-12-23 1995-11-14 Dsm Nv Werkwijze voor de bereiding van een alkanol en/of een alkanon.
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU3507297A (en) 1996-06-26 1998-01-14 Baylor College Of Medicine Chromosomal rearrangement by insertion of two recombination substrates
US6355412B1 (en) 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
AU2001236983A1 (en) * 2000-02-24 2001-09-03 Santen, Inc. Containers for preventing contamination from product labels
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
ATE501167T1 (de) * 2001-12-21 2011-03-15 Thrombogenics Nv Zusammensetzungen für die in vitro herleitung und kultur embryonaler stammzellinien mit keimbahnübertragungsfähigkeit und für die kultur adulter stammzellen
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ZA200804673B (en) 2005-12-13 2009-11-25 Univ Kyoto Nuclear reprogramming factor
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008118820A2 (en) 2007-03-23 2008-10-02 Wisconsin Alumni Research Foundation Somatic cell reprogramming
CA2683056C (en) 2007-04-07 2020-03-24 Whitehead Institute For Biomedical Research Reprogramming of somatic cells
JP2010528622A (ja) 2007-05-30 2010-08-26 ザ ジェネラル ホスピタル コーポレイション 体細胞から多能性細胞を生成する方法
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
KR20100103810A (ko) 2007-12-10 2010-09-28 알리바 바이오파마수티컬스, 아이엔씨. 동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
GB0915523D0 (en) 2009-09-07 2009-10-07 Genome Res Ltd Cells and methods for obtaining them
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
HUE047687T2 (hu) * 2011-02-25 2020-05-28 Regeneron Pharma ADAM6 egér
FI3865581T3 (fi) * 2011-08-05 2024-11-02 Regeneron Pharma Humanisoituja universaaleja kevytketjun hiiriä
US9706759B2 (en) * 2011-12-20 2017-07-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
EP3912465A1 (en) * 2012-02-01 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains

Also Published As

Publication number Publication date
EP2989894B9 (en) 2022-12-14
AU2012343587A1 (en) 2014-05-15
EP2649184A1 (en) 2013-10-16
AU2016101604A4 (en) 2016-10-06
EP2989894B1 (en) 2020-08-12
JP2015502149A (ja) 2015-01-22
EP4282879A3 (en) 2024-03-20
HK1185100A1 (zh) 2014-02-07
JP2020124228A (ja) 2020-08-20
AU2012343587B2 (en) 2016-07-14
AU2021203905A1 (en) 2021-07-08
JP2022159413A (ja) 2022-10-17
DE202012013369U1 (de) 2016-08-23
JP2018038428A (ja) 2018-03-15
US20160353719A1 (en) 2016-12-08
EP4282879A2 (en) 2023-11-29
AU2018217308A1 (en) 2018-09-06
EP2989894A1 (en) 2016-03-02
BR112014013121A2 (pt) 2019-09-24
AU2016244295A1 (en) 2016-11-03
EP3298889A1 (en) 2018-03-28
CN104160031B (zh) 2017-03-08
CN104160031A (zh) 2014-11-19
WO2013079953A1 (en) 2013-06-06
EP2649184B1 (en) 2015-10-07
US20130243759A1 (en) 2013-09-19
CA2857569A1 (en) 2013-06-06
ES2816899T3 (es) 2021-04-06
AU2016101604B4 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
GB201122047D0 (en) Transgenic animals
IL272357B (en) Histidine-engineered light chain antibodies, and non-human animals genetically modified for their preparation
EP4269602A3 (en) Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
IN2014MN01879A (enExample)
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
SMT201300046B (it) Modelli animali e molecole terapeutiche
IL264358A (en) Histidine engineered light chain antibodies and non-human animals genetically engineered to produce them
CY1122978T1 (el) Αντισωματα εναντι-vla-4
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
CR20140585A (es) Proteinas de union a antigeno st2
TR201810255T4 (tr) Modifiye edilmiş immunoglobulin ağır zincir sekanslarına sahip olan insan olmayan hayvanlar.
MX364328B (es) Conjugados del anticuerpo pirrolobenzodiazepina.
PL3181581T3 (pl) Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klierens antygenu
MY178142A (en) Anti-phf-tau antibodies and their uses
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
UY34411A (es) Inmunoenlazantes dirigidos contra esclerostina
MY173936A (en) Humanized light chain mice field of invention
WO2013063391A3 (en) Transgenic animals and methods of use
WO2015049517A3 (en) Animal models and therapeutic molecules
NZ703973A (en) Complex chromosome engineering for production of human antibodies in transgenic animals
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
EA201390660A1 (ru) Модифицированные никотиновые соединения и связанные способы
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)